Code Sets
To receive email updates about this page, enter your email address:
For more information on background and concepts see Understanding the Rules for Creating CVX and MVX Codes pdf icon[5 pages]
Preview Posting of COVID-19 Vaccine Codes and Crosswalk in Anticipation of Potential Vaccine Availability under Emergency Use Authorization (EUA)
Note: Codes will become effective only upon EUA issuance of COVID-19 vaccine(s) by the Food and Drug Administration (FDA)
The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress. Additional vaccines will be added to this list as they enter late-stage clinical trials.
The following downloadable table provides a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines currently being studied in clinical trials.
To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance.
The codes for these vaccines are also included in the vaccine code set files.
American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA web site. The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets. You can access further information regarding the COVID-19 CPT codes, as well as the associated coding guidance, using the following link:
Download the Preview Table: Preview COVID-19 Vaccine Codes Potential EUA 20201231excel icon
CVX Code | CVX Long Description | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC10 (UOS) | UoS Package | Unit of Use NDC10 (UOU) | Presentation | CPT Code | CPT Description |
---|---|---|---|---|---|---|---|---|---|---|---|
207 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose | COVID-19, mRNA, LNP-S, PF, 100 mcg/ 0.5 mL dose | Moderna COVID-19 Vaccine | Moderna US, Inc. | MOD | 80777-273-99 | CARTON, 10 MULTI-DOSE VIALS | 80777-273-10 | MULTI-DOSE VIAL, 10 DOSES | 91301 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use |
208 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | Pfizer COVID-19 Vaccine | Pfizer-BioNtech | PFR | 59267-1000-2 | CARTON, 195 MULTI-DOSE VIALS | 59267-1000-1 | MULTI-DOSE VIAL | 91300 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use |
208 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | Pfizer COVID-19 Vaccine | Pfizer-BioNTech | PFR | 59267-1000-3 | CARTON, 25 MULTI-DOSE VIALS | 59267-1000-1 | MULTI-DOSE VIAL | 91300 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use |
210 | SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | AstraZeneca COVID-19 Vaccine | AstraZeneca Pharmaceuticals LP | ASZ | 0310-1222-15 | CARTON, 10 MULTI-DOSE VIALS | 0310-1222-10 | MULTI-DOSE VIAL, 10 DOSES | 91302 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×1010 viral particles/0.5mL dosage, for intramuscular use |
Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers
Vaccine information statements (VISs), used only for licensed vaccines, will not be available for COVID-19 vaccines while they are under Emergency Use Authorization (EUA). For vaccines under an EUA, the FDA requires a vaccine-specific Fact Sheet for Recipients and Caregivers be provided to vaccine recipients or their caregivers.
The COVID-19 vaccine-related codes are provided in anticipation of potential vaccine availability under an EUA. If a vaccine is not authorized, the code will be retired.
The FDA issued Emergency Use Authorization for the Moderna COVID-19 vaccine on Friday December 18, 2020. Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:
The FDA issued Emergency Use Authorization for the Pfizer BioNTech COVID-19 vaccine on Friday December 11, 2020. Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:
The following downloadable VIS code files will include the new EUA Fact Sheet for Recipients records:
CVX Code | EUA Recipient/Caregiver Fact Sheet Description | Document Barcode String | Edition Date | Edition Status | HTML URL | PDF URL | VIS GDTI document code |
---|---|---|---|---|---|---|---|
207 | COVID-19 Moderna Vaccine EUA Recipient-Caregiver Fact Sheet | 253088698300034911201201 | 12/01/2020 | Current | https://www.cdc.gov/vaccines/covid-19/eua/modernatx.html | https://www.cdc.gov/vaccines/covid-19/eua/modernatx.pdfpdf icon | 0886983000349 |
208 | COVID-19 Pfizer BioNTech Vaccine EUA Recipient-Caregiver Fact Sheet | 253088698300033211201201 | 12/01/2020 | Current | https://www.cdc.gov/vaccines/covid-19/eua/pfizer.html | https://www.cdc.gov/vaccines/covid-19/eua/pfizer.pdfpdf icon | 0886983000332 |
*Edition date is the date of the barcode generated-edition date and does not reflect the exact date that the EUA Fact Sheet was issued.
2020/2021 Seasonal Influenza Codes and Crosswalk
This new format includes all seasonal influenza vaccines for the 2020/2021 season in a single Excel crosswalk table that provides the CVX, MVX, NDC Unit of Sale, NDC Unit of Use, and CPT (*) codes for each vaccine.
(*) Please note that the CPT codes shown for each vaccine crosswalk are not mapped to the NDC codes, but are mapped to the CVX codes shown. These are reference CPT codes for vaccine categorization and are not intended to represent billable codes.
Download the Seasonal Influenza Crosswalk tableexcel icon
CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
---|---|---|---|---|---|---|---|---|---|
149 | influenza, live, intranasal, quadrivalent | FluMist Quadrivalent | MedImmune, LLC | MED | 66019-0307-10 | 66019-0307-01 | APPLICATOR .2 mL | 90672 | Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use |
150 | influenza, injectable, quadrivalent, preservative free | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | IDB | 19515-0816-52 | 19515-0816-41 | SYRINGE, .5 mL | 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
150 | influenza, injectable, quadrivalent, preservative free | Afluria Quadrivalent | Seqirus Pty Ltd. | SEQ | 33332-0320-01 | 33332-0320-02 | SYRINGE, .5 mL | 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
150 | influenza, injectable, quadrivalent, preservative free | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | PMC | 49281-0420-10 | 49281-0420-58 | VIAL, .5 mL, SINGLE-DOSE | 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
150 | influenza, injectable, quadrivalent, preservative free | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | PMC | 49281-0420-50 | 49281-0420-88 | SYRINGE, .5 mL | 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
150 | influenza, injectable, quadrivalent, preservative free | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | SKB | 58160-0885-52 | 58160-0885-41 | SYRINGE, .5 mL | 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
158 | influenza, injectable, quadrivalent | Afluria Quadrivalent | Seqirus Pty Ltd. | SEQ | 33332-0420-10 | 33332-0420-11 | VIAL, 5 mL, MULTI-DOSE | 90687 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use |
90688 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | ||||||||
158 | influenza, injectable, quadrivalent | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | PMC | 49281-0633-15 | 49281-0633-78 | VIAL, 5 mL, MULTI-DOSE | 90687 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use |
90688 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | ||||||||
161 | Influenza, injectable,quadrivalent, preservative free, pediatric | Afluria Quadrivalent | Seqirus Pty Ltd. | SEQ | 33332-0220-20 | 33332-0220-21 | SYRINGE, .25 mL | 90685 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use |
161 | Influenza, injectable,quadrivalent, preservative free, pediatric | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | PMC | 49281-0520-25 | 49281-0520-00 | SYRINGE, .25 mL | 90685 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use |
168 | influenza, trivalent, adjuvanted | FLUAD | Seqirus, Inc. | SEQ | 70461-0020-03 | 70461-0020-04 | SYRINGE, .5 mL | 90653 | Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use |
171 | Influenza, injectable, MDCK, preservative free, quadrivalent | FLUCELVAX QUADRIVALENT | Seqirus Inc. | SEQ | 70461-0320-03 | 70461-0320-04 | SYRINGE, .5 mL | 90674 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use |
185 | influenza, recombinant, quadrivalent,injectable, preservative free | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0720-10 | 49281-0720-88 | SYRINGE, .5 mL | 90682 | Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use |
186 | Influenza, injectable, MDCK, quadrivalent, preservative | FLUCELVAX QUADRIVALENT | Seqirus Inc. | SEQ | 70461-0420-10 | 70461-0420-11 | VIAL, 5 mL, MULTI-DOSE | 90756 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use |
197 | influenza, high-dose, quadrivalent | FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0120-65 | 49281-0120-88 | SYRINGE, .7 mL | 90662 | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use |
205 | Influenza vaccine, quadrivalent, adjuvanted | FLUAD QUADRIVALENT | Seqirus, Inc. | SEQ | 70461-0120-03 | 70461-0120-04 | SYRINGE, .5 mL | 90694 | Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use |
CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation |
---|---|---|---|---|---|---|---|
200 | influenza, Southern Hemisphere, pediatric, preservative free | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0181-25 | 49281-0181-00 | Syringe, glass, .25 mL |
201 | influenza, Southern Hemisphere, preservative free | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0320-50 | 49281-0320-88 | Syringe, glass, .5 mL |
202 | influenza, Southern Hemisphere, quadrivalent, with preservative | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0336-15 | 49281-0336-78 | Vial, 5 mL, MULTI-DOSE |